The effect of the active metabolite enalaprilat on the angiotensin II/angiotensin I ratio was adequately described by the pharmacokinetic/pharmacodynamic model developed for healthy adults and the pharmacodynamic model developed for children with heart failure. This evidence concerns the gene AGT and heart failure.